Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

NCT01709435 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01709435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01709435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2012
Completion date
December 31, 2019
Enrollment
41 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent malignant solid neoplasm, recurrent melanoma, recurrent primary central nervous system neoplasm, recurrent thyroid gland carcinoma, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm, thyroid gland medullary carcinoma